VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction – A single centre, randomized, parallel-group, double-blind clinical trial, for assessing the effectiveness of pharmacological myocardial conditioning in STEMI using vildagliptin.

Trial Profile

VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction – A single centre, randomized, parallel-group, double-blind clinical trial, for assessing the effectiveness of pharmacological myocardial conditioning in STEMI using vildagliptin.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms VIPER-AMI
  • Most Recent Events

    • 20 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top